Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer

被引:130
|
作者
Stoehr, R
Wissmann, C
Suzuki, H
Knuechel, R
Krieg, RC
Klopocki, E
Dahl, E
Wild, P
Blaszyk, H
Sauter, G
Simon, R
Schmitt, R
Zaak, D
Hofstaedter, F
Rosenthal, A
Baylin, SB
Pilarsky, C
Hartmann, A
机构
[1] Univ Basel, Inst Pathol, CH-4031 Basel, Switzerland
[2] Univ Regensburg, Inst Pathol, D-8400 Regensburg, Germany
[3] metaGen Pharmaceut GmbH, Berlin, Germany
[4] Johns Hopkins Univ, S Kimmel Compreh Canc Ctr, Baltimore, MD USA
[5] Rhein Westfal TH Aachen, Univ Clin, Inst Pathol, Aachen, Germany
[6] Univ Vermont, Inst Pathol, Burlington, VT 05405 USA
[7] Univ Regensburg, Dept Genet, D-8400 Regensburg, Germany
[8] Univ Munich, Dept Urol, Munich, Germany
关键词
bladder cancer; chromosome; 8; sFRP1; TMA; LOH; promoter methylation;
D O I
10.1038/labinvest.3700068
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Many molecular alterations are known to occur in urothelial carcinoma of the bladder, but their significance for tumor progression is poorly understood. Deletions of chromosome 8p are frequently found in several tumor types and are often associated with progressive disease. In all, 99 bladder tumors were screened for deletions at 8p using loss of heterozygosity (LOH) and multicolor fluorescence in situ hybridization FISH analyses. Allelic loss on chromosome 8p in at least one marker was found in 25/99 (25%) tumors. There was a significant correlation of 8p deletions with invasive tumor growth and a highly significant association with papillary growth pattern in patients with invasive disease. cDNA array analyses revealed that secreted Frizzled-related protein 1 (sFRP1), an antagonist of Frizzled receptors and Wnt pathway activation on chromosome 8p12-11.1, is frequently downregulated in bladder cancer. To investigate sFRP1 as a candidate for a putative progression-related gene on 8p, urothelial cell lines and primary urothelial carcinomas were screened for sFRP1 expression using quantitative real-time PCR, Northern blot, immunofluorescence and immunohistochemistry (IHC). Of the investigated bladder cancers, 38% showed loss of sFRP1 expression by quantitative RT-PCR. Evaluation of the protein expression by IHC using tissue microarrays containing 776 bladder cancers revealed loss or strong reduction of sFRP1 expression in 66% of cases. SFRP1 loss was associated with higher tumor stage and grade and shorter overall survival. In addition, loss of sFRP1 was an independent indicator of poor survival in patients with papillary but not with muscle invasive bladder cancer. There were neither mutations in the coding region of sFRP1 nor homozygous deletions at 8p12-11.21. However, promoter methylation was detected using methylation-specific PCR in 29% of cases. In conclusion, we could show a close correlation of chromosome 8p deletions and progression of papillary bladder tumors. The sFRP1 gene on chromosome 8p12-11.1 could be a candidate gene for the predicted, progression-related tumor suppressor gene in bladder cancer and could contribute to urothelial carcinogenesis.
引用
收藏
页码:465 / 478
页数:14
相关论文
共 50 条
  • [1] Functional characterization of sFRP1 expression loss in human papillary bladder cancer
    Rogler, Anja
    Hartmann, Arndt
    Goebell, Peter
    Wullich, Bernd
    Stoehr, Robert
    [J]. CANCER RESEARCH, 2011, 71
  • [2] MAPPING OF CHROMOSOME 8P DELETIONS IN BLADDER-CANCER
    TAKLE, LA
    KNOWLES, MA
    [J]. CYTOGENETICS AND CELL GENETICS, 1995, 68 (3-4): : 162 - 162
  • [3] MTUS1 as a potential progression marker at chromosome 8p in bladder cancer
    Rogler, Anja Paola
    Hoja, Sabine
    Ekici, Arif
    Wullich, Bernd
    Goebell, Peter
    Hartmann, Arndt
    Stoehr, Robert
    [J]. CANCER RESEARCH, 2012, 72
  • [4] Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer
    Wagner, U
    Bubendorf, L
    Gasser, TC
    Moch, H
    Gorog, JP
    Richter, J
    Mihatsch, MJ
    Waldman, FM
    Sauter, G
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1997, 151 (03): : 753 - 759
  • [5] The role of 8p deletions in breast cancer development and progression
    Cai, Y.
    Crowther, J.
    Sablina, A.
    [J]. FEBS JOURNAL, 2014, 281 : 510 - 510
  • [6] CHROMOSOME 8P LOSS OF HETEROZYGOSITY DEFINED BY MICROSATELLITE REPEAT MARKERS - FREQUENT DELETIONS IN COLORECTAL AND LUNG CARCINOMAS
    KELEMEN, PR
    YAREMKO, ML
    KIM, A
    MINNA, J
    WESTBROOK, CA
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 195 - 195
  • [7] Functional analyses and prognostic significance of SFRP1 expression in bladder cancer
    Anja Rogler
    Emil Kendziorra
    Johannes Giedl
    Christine Stoehr
    Helge Taubert
    Peter J. Goebell
    Bernd Wullich
    Michael Stöckle
    Jan Lehmann
    Sabrina Petsch
    Arndt Hartmann
    Robert Stoehr
    [J]. Journal of Cancer Research and Clinical Oncology, 2015, 141 : 1779 - 1790
  • [8] Frequent loss of sFRP1 expression and sFRP1 promoter methylation in prostate cancer and adjacent histopathotogically normal prostate
    Strohr, R.
    Hader, C.
    Florl, A. R.
    Dahl, E.
    Burger, M.
    Tannapfel, A.
    Wieland, W.
    Schulz, W. A.
    Hartmann, A.
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2007, 203 (05) : 320 - 321
  • [9] Functional analyses and prognostic significance of SFRP1 expression in bladder cancer
    Rogler, Anja
    Kendziorra, Emil
    Giedl, Johannes
    Stoehr, Christine
    Taubert, Helge
    Goebell, Peter J.
    Wullich, Bernd
    Stoeckle, Michael
    Lehmann, Jan
    Petsch, Sabrina
    Hartmann, Arndt
    Stoehr, Robert
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (10) : 1779 - 1790
  • [10] Chromosome 8p Deletions and 8q Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer
    El Gammal, Alexander T.
    Bruechmann, Michael
    Zustin, Jozef
    Isbarn, Hendrik
    Hellwinkel, Olaf J. C.
    Koellermann, Jens
    Sauter, Guido
    Simon, Ronald
    Wilczak, Waldemar
    Schwarz, Joerg
    Bokemeyer, Carsten
    Bruemmendorf, Tim H.
    Izbicki, Jakob R.
    Yekebas, Emre
    Fisch, Margit
    Huland, Hartwig
    Graefen, Markus
    Schlomm, Thorsten
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (01) : 56 - 64